Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion
- PMID: 18997839
- DOI: 10.1038/jid.2008.330
Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion
Abstract
The anti-CD20 mAb rituximab, first approved for use in B-cell malignancies, is increasingly used to treat a variety of autoimmune diseases. Two studies in this issue investigate the effects of rituximab in pemphigus. Rituximab induces not only a depletion of all B cells and a decline of antidesmoglein autoantibodies but also a decrease in desmoglein-specific T cells. Furthermore, B-cell populations recovered after treatment were modified. These novel aspects may contribute to the clinical responses observed in patients.
Comment on
-
B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses.J Invest Dermatol. 2008 Dec;128(12):2859-69. doi: 10.1038/jid.2008.178. Epub 2008 Jun 19. J Invest Dermatol. 2008. PMID: 18563177
-
Rituximab exerts a dual effect in pemphigus vulgaris.J Invest Dermatol. 2008 Dec;128(12):2850-8. doi: 10.1038/jid.2008.172. Epub 2008 Jun 19. J Invest Dermatol. 2008. PMID: 18563178
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
